Comparison of two dosing schedules of palonosetron for the prevention of nausea and vomiting due to interleukin-2-based biochemotherapy

Rahat Noor, Agop Y. Bedikian, Sandy Mahoney, Roland Bassett, Kevin Kim, Nicholas Papadopoulos, Wen Jen Hwu, Patrick Hwu, Jade Homsi

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Background Treatment of metastatic melanoma with interleukin-2-based biochemotherapy involves administration of a combination of moderately and highly emetogenic chemotherapies over 5 days. Corticosteroids for the prevention of biochemotherapy-induced nausea and vomiting (CINV) are contraindicated because they cause lysis of LAK cells produced in response to interleukin-2. Palonosetron is a long-acting, highly potent, second-generation serotonin receptor antagonist. The recommended dosing schedule of palonosetron for the control of CINV due to biochemotherapy is not known. Methods In a phase II design, treatment-naïve patients with metastatic melanoma undergoing the first cycle of biochemotherapy were randomized to receive palonosetron 0.25 mg intravenously for CINV prophylaxis on either days 1 and 4 (schedule 1) or days 1, 3, and 5 (schedule 2). All patients received dacarbazine on day 1, cisplatin, vinblastine, and interleukin-2 on days 1-4, and interferon alpha-2b on days 1-5. We evaluated and compared, by palonosetron dosing schedule, the pattern and the severity of CINV during the first 7 days of treatment and the duration of the 21-day cycle as well as the impact on daily function with the Functional Living Index Emesis. Results Thirty patients (median age 53 years) were enrolled. Eighteen (60%) were men. A consistent trend of a better control of both nausea and vomiting favoring schedule 2 was observed during the first 7 days and throughout the cycle. Significantly more patients experienced nausea on any day during the first 7 days on schedule 1 (mean number of episodes 8.1±1.5) than on schedule 2 (mean number of episodes 5.6±2.3, p00.028). The impact on daily function was similar between the two groups. Conclusions Both dosing schedules of palonosetron were tolerated well. Alternate day dosing of palonosetron was more effective in controlling CINV in this patient population.

Original languageEnglish (US)
Pages (from-to)2583-2588
Number of pages6
JournalSupportive Care in Cancer
Volume20
Issue number10
DOIs
StatePublished - Oct 1 2012

Keywords

  • Biochemotherapy
  • Cancer
  • Melanoma
  • Nausea
  • Palonosetron .Vomiting

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Comparison of two dosing schedules of palonosetron for the prevention of nausea and vomiting due to interleukin-2-based biochemotherapy'. Together they form a unique fingerprint.

  • Cite this